Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. The safety profile and progression free survival were similar to phase III trial results. —> Read More